The objective of this study was to describe trends in the use of hormone replacement therapy (HRT) in the United States by demographic, life-style, and heart disease risk factors. Data were obtained from the Epidemiologic Followup Study to the First National Health and Nutrition Examination Survey, a nationally representative cohort followed from the mid-1970s until 1992. A total of 5,602 women who had become menopausal by their last follow-up interview were included. An estimated 45% of the cohort of menopausal US women 25-74 years of age in the early 1970s used HRT for at least one month and 20% continued use for 5 or more years. Between 1987 and 1992, as the younger members of the cohort became menopausal, the proportion of this cohort who had ever used HRT and used it for 5 or more years increased by 32% and 54%, respectively. A higher probability of HRT use was found among women who were white, who were more highly educated, and who lived in the West, or who had experienced a surgical menopause. Women who were overweight or who abstained from alcohol were less likely to use HRT. These data support the hypothesis that HRT use is associated with sociodemographic factors, and that women tend to discontinue use within several years. Am J Epidemiol 1997;145:536-45. cohort studies; estrogen replacement therapy; menopause; risk factors
The objective of this study was to describe trends in the use of hormone replacement therapy (HRT) in the United States by demographic, life-style, and heart disease risk factors. Data were obtained from the Epidemiologic Followup Study to the First National Health and Nutrition Examination Survey, a nationally representative cohort followed from the mid-1970s until 1992. A total of 5,602 women who had become menopausal by their last follow-up interview were included. An estimated 45% of the cohort of menopausal US women 25-74 years of age in the early 1970s used HRT for at least one month and 20% continued use for 5 or more years. Between 1987 and 1992, as the younger members of the cohort became menopausal, the proportion of this cohort who had ever used HRT and used it for 5 or more years increased by 32% and 54%, respectively. A higher probability of HRT use was found among women who were white, who were more highly educated, and who lived in the West, or who had experienced a surgical menopause. Women who were overweight or who abstained from alcohol were less likely to use HRT. These data support the hypothesis that HRT use is associated with sociodemographic factors, and that women tend to discontinue use within several years. Am J Epidemiol 1997;145:536-45. cohort studies; estrogen replacement therapy; menopause; risk factors Use of postmenopausal hormone replacement therapy (HRT) has fluctuated over the past 50 years due to changes in the perception of its risks and benefits. Although first approved in the 1940s, unopposed estrogen replacement therapy became widely used starting in the 1960s (1) . Use declined in the 1970s after the publication of reports of an association between estrogen use and uterine carcinoma (2, 3) . With the introduction of combined estrogen/progestin hormone therapy in the 1980s, HRT has regained its popularity (4, 5) . These drugs are currently among the most commonly prescribed medications in the United States, and were taken by an estimated 2.9 million women in 1986 (6, 7), increasing to an estimated 6 million women in 1992 (8) .
The identification of several important effects of HRT beyond the reduction of menopausal symptoms, both protective and adverse, has increased interest in this drug therapy. Unopposed estrogen therapy appears to be associated with a reduced risk of both heart disease (9-11) and osteoporotic fractures (12) , especially among current and long-term users. However, postmenopausal estrogen use increases the risk of uterine cancer (9) and may increase the risk of breast cancer (13) . While the addition of progestin to HRT is not expected to change its association with osteoporosis, its effect on the risk of heart disease and breast cancer is less certain (9) .
Several cross-sectional and cohort studies in the United States have reported estimates of HRT use (5, (14) (15) (16) (17) (18) (19) (20) (21) (22) . These studies have yielded estimates of the proportion of postmenopausal women who take HRT in the selected studied populations ranging from 12 percent (17) to 47 percent (20) . This disparity is due to many factors, including the time at which the data were collected, and the demographics and location of the study population. Women who take HRT appear to be healthier, more affluent, and more likely to undertake health promotion and disease prevention activities (6, (23) (24) (25) . This has led to the conclusion by some that the association between HRT use and reduced heart disease incidence may be partially due to selection bias, although this remains controversial (26, 27) .
Because the estimates of HRT use to date have been derived from studies of specific communities or occupational groups, they may not be generalizable to the United States as a whole. This is especially true because regional variation in use has previously been identified, with women in the Northeast having the lowest prevalence of use and women in the West the highest (4, 28) . In this paper, we examine the cumulative incidence of HRT use and covariates of HRT use within a representative cohort derived from a representative sample of US women. We document the pattern of use in terms of duration and whether combination therapy was used in order to more fully describe the experience of US women in this birth cohort.
MATERIALS AND METHODS
The study population used for this analysis was taken from the Epidemiologic Followup Study to the First National Health and Nutrition Examination Survey (NHEFS). This is a prospective cohort study of subjects who completed the First National Health and Nutrition Survey (NHANES I) in 1971 to 1975. Follow-up waves have been conducted in 1982-1984, 1986, 1987, and 1992 (29-31) . The 1986 The , 1987 , and 1992 NHEFS interviews were conducted by telephone, whereas the 1982-1984 interviews were conducted in person. Reproductive questions in 1982-1984 were obtained through the use of selfadministered written questionnaires in an effort to provide subject privacy.
HRT questions were first asked as part of the 1982-1984 follow-up. At subsequent follow-up interviews, women who were not previously interviewed or were not previously menopausal were asked the entire battery of retrospective questions while those who had provided information on HRT in a prior interview were only asked to update their previous responses.
The wording and type of the HRT questions changed over the course of the follow-up period to take into account changes in the type of HRT formation in use at the time. Hormone use was derived primarily from the questions which asked whether or not a woman had taken "hormone pills for reasons related to menopause," the age at last use of these pills, and the total number of months or years of use. These questions were asked at every follow-up. An additional question about the use of "an estrogen or hormone skin patch" was included in the last follow-up, when this mode of administration had become more common. Questions regarding whether the respondent took progestin were asked of women who were current HRT users at the 1987 follow-up and of all women who had ever used HRT at the 1992 follow-up. Therefore, designation of the type of HRT (estrogen only or combination estrogen and progestin) could only be made for a subsample of HRT users. NHEFS did not ask the name of the drug, nor has an attempt been made to verify drug data.
Because the validity and reliability of information obtained from self-administered questionnaires such as that used in the 1982-1984 follow-up are lower than information obtained by an interviewer, especially in low education populations (32) , data regarding HRT use were taken from the 1987 survey even when the same information was also available from the selfadministered 1982 questionnaire (i.e., for women who ceased use before the 1982 interview, 244 of the 1,902 women in this category changed their responses to questions concerning the total number of months of use, but did not to change response regarding ever use of HRT). Data from interviews conducted with proxies were also excluded from this analysis because proxies would be less able to accurately answer medication and menopausal questions.
A variety of sociodemographic, health behavior, and heart disease predictor variables were included in these analyses. The covariates obtained by self-report at the baseline interview were the following: highest grade of education completed (<high school, high school, >high school), ethnicity (black, white, other), alcohol consumption (never, < 1 drink/month, 1 drink/ month-<l drink/day, ^1 drink/day), recreational activity (low, moderate-high), and oral contraceptive use (ever, never). Baseline smoking status (current, former, never) was obtained either at baseline, the first follow-up interview, or, if both of these sources of information were missing, imputed using data from respondents of the same gender and age (33) . Selfreported health (excellent, good, fair-poor) was obtained from the follow-up interviews because it was not included in the baseline interview. Medical risk factors considered from the baseline interview were history of self-reported diabetes mellitus, hypertension (defined by self-report of hypertension, or having systolic blood pressure over 160 mmHg or diastolic blood pressure over 95 mmHg), high serum cholesterol (^200 mg/dl), and being overweight (body mass in-
2 ) >120 percent of the national average of 27.3 kg/m 2 ). Type of menopause was derived from the first interview administered after menopause. This was defined as follows: 1) natural menopause-having no periods or having irregular periods because they are going through the change of life; 2) surgical menopause-having had a bilateral oophorectomy before natural menopause; or 3) after hysterectomy-having had a hysterectomy without oophorectomy before natural menopause. Age at menopause was defined as the age when menses had stopped for 12 months for natural menopause, age at bilateral oophorectomy, or imputed as the average age at natural menopause (48 years) for women who experienced hysterectomy without bilateral oophorectomy. Year of menopause was birth year plus age at menopause.
Several criteria were used to determine eligibility for inclusion in this analysis. Of the 8,596 women examined in NHANES I, 1,681 were eliminated because they had not been personally interviewed during any of the follow-up interviews (i.e., they were either lost to follow-up or a proxy was interviewed due to the death or incapacitation of the subject). An additional 1,142 women had not become menopausal at the time of the last interview. Nineteen women were missing information on HRT use and an additional 152 women were missing information on one or more of the covariates of interest and were therefore eliminated, leaving 5,602 for analysis. This cohort of women has been followed for an average of 17.5 years and ranged in age from 25 to 74 years at the baseline examination.
Several analyses were conducted whose purpose was the identification of covariates of HRT use. Information on these potential covariates was obtained either at baseline or at the first follow-up. For many women, menopause occurred many years prior to the measurement of the covariates, which would not allow us to identify the temporal relation between covariates and outcome. To control for this, we limited analyses of covariates to women who had become menopausal during or after the year of the baseline examination. This reduced the analytic sample to 2,784 women. The age of women in this group ranged from 25 to 66 years at the baseline examination. This group of women has been followed for an average of 18.8 years.
HRT use was described for the whole cohort in terms of ever use and length of use. Age at last use and use for more than 5 years were investigated using only those women who indicated use for at least one month. Use of estrogen only or combination HRT was also analyzed for the 1,990 women who indicated ever use of HRT in the 1992 follow-up wave (complete information on combination therapy was not available from earlier waves).
We also were interested in identifying potential effect modifiers of these associations. Year and type of menopause, ethnicity, and education were examined as potential effect modifiers in the analysis of ever use of HRT. Due to limited sample sizes for other use variables, interactions were not investigated in their analysis. Interactions were considered significant if the p value of the Wald statistic was less than 0.10 and all the stratified sample sizes were at least 30 (1 percent of the cohort).
Bivariate analyses were conducted using contingency tables. Logistic regression models were used to control for several factors simultaneously. While NHEFS data are best analyzed using techniques that take the differing lengths of follow-up into account (34) , the lack of a beginning date of HRT use for 6 percent of HRT users precluded the use of survival techniques. Test-based confidence intervals were constructed around relative risk estimates. The NHEFS cohort was derived from a national probability sample with selection probabilities that varied by age, sex, residence, and income. In order to obtain representative estimates of US women, SUDAAN software was used to calculate weighted estimates of the various associations with HRT use and the corrected standard errors of these estimates (35) . Statements regarding the sample were obtained from simple, unweighted calculations.
RESULTS
The mean reported age at menopause for the 83 percent of women in the NHEFS sample who had experienced menopause was 45.9 years (range 16-77 years). Twenty-two percent of the study cohort experienced menopause as a result of a bilateral oophorectomy; the age at menopause among this group was 40.1 years compared with 47.5 years among women who had experienced menopause naturally. Age at menopause would be slightly higher had 100 percent of the study population experienced menopause, as the women still premenopausal by follow-up end were slightly older. By the last interview, the average age of the study cohort was 66.4 years. Table 1 presents information regarding the study cohort by year of birth. Because not all women born in 1935 or later had experienced menopause at the time of their last interview, a smaller proportion of these birth cohorts were included in this study and their average age at menopause was younger than in the earlier cohorts because a large proportion of menopausal women in this birth cohort experienced surgical menopause. The use of HRT increases with year of birth. Only 19 percent of women born between 1885 and 1904 used HRT while 46 percent of those born between 1925 and 1934 used HRT. Usage in the youngest cohort is higher, which reflects the relatively small proportion of the cohort that had experienced menopause and the higher prevalence of surgical menopause in this group. Variation in usage by cohort reflects the availability of HRT when these cohorts became menopausal as well as beliefs concerning HRT at these times.
As estimated by this sample, 45 percent (95 percent confidence interval (CI) 43-47) of US women born between 1897 and 1950 who were menopausal by 1992 had used HRT for at least one month. The estimate of use for the whole cohort may change as the remainder of the cohort experiences menopause. Use varied greatly by year and type of menopause (figure 1). Among women who experienced menopause due to a bilateral oophorectomy, the group most likely to use HRT throughout the time period, use increased from 37 percent among women who became menopausal before 1945 to 71 percent for women who became menopausal in 1990-1992. In this group of women, the prevalence peaked among those who experienced menopause between 1965 and 1969 and then remained relatively stable. The proportion of women who underwent menopause naturally who were ever-users has increased from 11 percent among women who were menopausal earliest to 46 percent among women who were menopausal in 1990-1992, 38 percent less than women who had a oophorectomy. In this group, prevalence increased for each cohort until the early 1970s when it declined somewhat and then began rising at a slower pace starting among those who were menopausal in the early 1980s. Although the estimates are less precise among women who had hysterectomies without bilateral oophorectomy, the use of HRT among this group tended to be between the other two groups.
Among women who experienced menopause no earlier than the baseline examination (n = 2,784), surgical menopause, white race, and higher alcohol con- sumption were independently associated with an increased probability of HRT use (table 2) . HRT use also varied by residence, with women in the West most likely to use HRT, and those who resided in the Northeast the least likely. Not being overweight and taking oral contraceptives were also found to be associated with increased probability of HRT use. However, after controlling for other factors, HRT use did not vary significantly by self-reported health, recreational activity, or smoking. Fifty-six percent of women who had previously used oral contraceptives also had used HRT at some point, resulting in an estimated 28 percent having taken both drug therapies. In this and all subsequent analyses, serum cholesterol level, diabetes mellitus, and hypertension were not associated with HRT use and so were not included in the logistic models. There were no significant interactions found in the association with HRT use.
The length of HRT use was available for 2,287 of the 2,342 women (98 percent) in the sample who ever used HRT. The median length of use was 36 months, while the mean length of use was 6.6 years. Fortythree percent (95 percent CI39-47) of ever users used HRT for at least 5 years, and 20 percent of all women in the cohort used HRT for at least this long.
In a multivariate analysis of the 1,036 women who had used HRT and were followed for at least 5 years after menopause, women who had experienced menopause after bilateral oophorectomy were 1.9 times more likely to continue HRT use for at least 5 years than women who had a natural menopause (table 3) . Women with more than a high school education were significantly more likely to continue HRT use for at least 5 years compared with women with less than a high school education. Black women were less than one-third as likely to continue HRT use for 5 years (odds ratio (OR) = 0.3, 95 percent CI 0.2-0.6) as women of other races. Women who were more than 20 percent overweight were also less likely to use HRT for at least 5 years than women who had a low body mass index (OR = 0.6, 95 percent CI 0.4-1.0). Residents of the West were significantly more likely than women who lived in the Northeast to continue HRT use for 5 years, but were not significantly different from women who lived in the Midwest and South. Finally, women who consumed at least one alcoholic beverage per month were more likely to continue HRT use than women who consumed little or no alcohol.
Thirty-one percent (95 percent CI 28-33) of women interviewed in 1992 who had used HRT took progestin while the remaining 69 percent of the women indicated they used estrogen only. Several of the variables which were associated with use of any HRT were also associated with use of combination therapy rather than estrogen only: non-black race, college education, use of oral contraceptives, and body mass index less than 120 percent of average (table 4) . Natural menopause was associated with more than three times the likelihood of combination HRT use compared with either menopause after bilateral oophorectomy or hysterectomy.
DISCUSSION
While the NHEFS cohort has the strength of being a nationally representative cohort study, this study design has limitations relevant to this investigation. Selfreport of menopausal estrogen use has been previously found to be fairly well reported, although the more detail requested, the less reliable the data become (36, 37) . The agreement between physicians' records and interview data in one study was 87 percent (36) , both for use and non-use. When we duplicated the analysis of ever-use including only the 3,523 women who were no more than 10 years beyond menopause at baseline and therefore more likely to reliably report HRT use (36) , similar results were obtained.
We were able to check the consistency of HRT reporting among the women who completed at least two interviews in which they answered HRT questions. Only 4 percent said they had used HRT during the one interview but contradicted this information in a subsequent interview. Of the women who said they had used HRT, however, more than 30 percent reduced the length of time they reported using HRT by more than 6 months in either 1987 or 1992 compared with what they reported in 1982, while only 13-15 percent estimated their length of use to have increased by more than the time between the survey waves.
The wording of the NHEFS questions may have underestimated total HRT use. In the 1970s, injectable estrogens were used with about equal frequency as oral estrogens (4) . The question used in this study prior to 1992 only asked about "hormone pills." Furthermore, noncontraceptive estrogen was used during this time period for indications other than "reasons related to menopause," such as prevention of osteoporosis (7) .
Only data that were obtained from the subject, and not a proxy, were used to increase the reliability of the HRT use estimates. Follow-up interviews were obtained with 90 percent of the 4,584 women in the NHEFS study population who were still experiencing menses within 12 months of the baseline examination, and 97 percent of these women were personally interviewed at least once. If women who are healthier, and therefore do not need a proxy respondent, tend to use HRT, the estimates of use may have been inflated. This bias would not be great due to the small proportion of lost subjects. Many of the variables identified in this study to be associated with HRT use have previously been identified as covariates. The consistent association between HRT use and lean body size (5, (14) (15) (16) (17) (18) (19) (20) (21) (22) and surgical menopause (5, 17, (19) (20) (21) (22) probably reflects the targeting of HRT toward women with lower exposure to endogenous estrogen. Education or socioeconomic status (15-17, 19, 21) and race (17) may be indicators of differential in health behaviors and access to health care. The temporal trends in HRT use found here are well established (7), although they have tended to be addressed as an association between age and HRT use (5, 14, 16-19, 21, 39) .
The association between regular alcohol consumption and average amount consumed has been found in some studies but not all studies (14, 15, 17, 19, 20, 22, 39) . Because alcohol consumption by women at moderate levels is positively related to socioeconomic status (38) , the increased use of HRT by women who also consumed alcohol may be identifying another component of the positive association between socioeconomic status and HRT which was not captured by education level. Alternatively, alcohol consumption may influence HRT use through some other pathway.
The finding that women who exercised regularly at baseline were no more likely to use HRT than nonexercisers when other factors were controlled is inconsistent with several other studies' results (18) (19) (20) (21) (22) 39) . When the data were reanalyzed using the most recent self-report of recreational activity to define exercise levels, HRT users were significantly more likely to exercise than nonusers, although this difference is not significant after controlling for other variables. The baseline exercise questions were not detailed and so may not have differentiated exercise in sufficient detail.
High serum cholesterol, hypertension, smoking, and diabetes mellitus, factors that are strongly related to heart disease, had no independent relation with HRT use. Neither blood pressure (10, 14, 21, 39) nor total * NHEFS, Epidemiologic Followup Study to the First National Health and Nutrition Examination Survey, t All pencents were standardized for year of menopause. £ Adjusted odds ratios, controlling for all other variables considered significant Analysis was conducted on the 1,036 women followed for at least 5 years after menopause.
§ Cl, confidence interval. H A substantial proportion of women were not at risk of being exposed to HRT for this length of time due to the timing of menopause and so estimates are not given.
# These variables were not included in the multivariate models.
cholesterol (10, 21, 39) has been found to have a significant association with HRT use in previous studies, although HRT users have been found to have higher high density lipoprotein and lower low density lipoprotein cholesterol levels (5, 14, 15, 21, 39) . No consistent association has been found between HRT use and smoking. The use of progestin is important to reduce the risk of endometrial cancer among HRT users with intact uteri (9) . Even though women in this study who underwent a natural menopause were more than three times as likely to have taken progestin as women who experienced menopause after either a hysterectomy or oophorectomy, 20 to 30 percent of women who had undergone a hysterectomy and therefore were not at risk of uterine cancer reported using progestin. Use of progestin may lessen the potential benefit of estrogen use on coronary artery disease risk (9) . Additionally, the effects of long-term use of progestin in combination with estrogen remain unknown (8) , which raises concern regarding the use of progestin, especially by women who are not at risk of uterine cancer.
The data from this study suggest that 20 percent of women who experienced menopause between 1970 and 1992 used HRT for at least 5 years, while 25 percent took HRT for at least one month but for less than 5 years. White race, higher education, alcohol consumption, and menopause that occurred between 1960 and 1974 were independently associated with increased probability of use, while residence in the Northeast and obesity decreased the probability of use. These data also indicate that several demographic and health indicators were related to sustained use over 5 or more years and to the use of progestin. These data also suggest national use of HRT is increasing among the birth cohorts studied, because use increased from 38 to 50 percent between the 1987 and 1992 followups. Additional information in regard to national use patterns among all birth cohorts is needed to validate this finding. 
